Mark J. Gabrielson, CEO and President of Ore, said, "Jim Fordyce is a wonderful addition to our Board. He has expertise in corporate development, public finance, health sciences venture capital and acquisitions. His investment and management track records have been highly successful over a long period of time. On top of all that, Jim's dedication to the support and development of medical research through his life-long commitment to the Albert and Mary Lasker Foundation, Inc. shows that he holds progress in human health as a personal priority. We at Ore are delighted that he's joining us."
Fordyce is currently Managing Partner of MEDNA Partners, a private advisory firm. From 1981 to 2004, he was a general partner of Prince Ventures, a venture capital management firm focused on investments in medicine and the life sciences. His early investments include Genentech, Applied Biosystems, Centocor and Regeneron Pharmaceuticals amongst other noteworthy health sciences companies. From 1998 to 2004, Fordyce also served as the Managing Member of Fordyce & Gabrielson, a private investment management firm. He is currently a member of the Board of Directors of Dyax Corp. and several privately held companies. He is Chairman Emeritus of the Board of Directors of the Albert and Mary Lasker Foundation. Fordyce is a graduate of the University of Pennsylvania, Magdalen College, Oxford University and holds an MBA from Harvard Business School.
Ore Pharmaceuticals Inc. is a pharmaceutical asset management company with a focus on acquiring and developing clinical-stage drug candidates that have already undergone substantial safety testing in humans.
((Comments on this story may be sent to health@closeupmedia.com))

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index